---
created: '2026-02-08T19:45:44.495431Z'
description: A progressive neurodegenerative disorder characterized by motor symptoms
  including tremor, rigidity, and bradykinesia, caused by dopaminergic neuron loss
  in the substantia nigra and alpha-synuclein aggregation.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/condition/parkinsons-disease/
slug: parkinsons-disease
tags:
- condition
- neurodegeneration
- movement-disorder
- dopamine
title: Parkinson's Disease
type: condition
updated: '2026-02-08T19:45:44.495431Z'
---

# Parkinson's Disease

## Overview
Parkinson's Disease (PD) is the second most common neurodegenerative disorder after Alzheimer's Disease. It primarily affects the dopaminergic neurons in the **substantia nigra pars compacta**, leading to motor dysfunction. The pathological hallmark is the presence of **Lewy bodies** containing aggregated **alpha-synuclein** protein.

## Cardinal Motor Symptoms
1. **Tremor**: Resting tremor, typically "pill-rolling"
2. **Rigidity**: Increased muscle tone, "cogwheel" rigidity
3. **Bradykinesia**: Slowness of movement initiation and execution
4. **Postural Instability**: Balance and gait disturbances (late stage)

## Non-Motor Symptoms
- REM sleep behavior disorder (often prodromal)
- Anosmia (loss of smell)
- Constipation and autonomic dysfunction
- Depression and anxiety
- Cognitive impairment progressing to dementia

## Key Mechanisms
1. **Alpha-Synuclein Aggregation**: Misfolded alpha-synuclein forms toxic oligomers and Lewy bodies
2. **Mitochondrial Dysfunction**: Complex I deficiency and oxidative stress
3. **Neuroinflammation**: Microglial activation and pro-inflammatory cytokines
4. **Impaired Proteostasis**: Dysfunction in autophagy-lysosomal and ubiquitin-proteasome systems

## Genetic Risk Factors
- **SNCA**: Encodes alpha-synuclein; duplications/triplications cause familial PD
- **LRRK2**: Most common cause of familial PD; kinase activity inhibitors in development
- **GBA1**: Glucocerebrosidase mutations; strongest genetic risk factor for sporadic PD
- **PINK1/Parkin**: Mitophagy pathway genes; early-onset PD

<!-- NEO4J_CONTENT_START -->
## Relationships
### Related
- ← [[Alpha-Synuclein_SAA]] (examination)
```yaml
last_modified: '2026-01-26T07:07:44.082636'
source: obsidian
```
- ← [[DAT-SPECT]] (examination)
```yaml
last_modified: '2026-01-26T07:07:44.395203'
source: obsidian
```
- ← [[Retinal_Imaging_for_Neurodegeneration]] (examination)
```yaml
last_modified: '2026-01-26T07:07:45.549973'
source: obsidian
```
- ← [[Sleep_Optimization]] (intervention)
```yaml
last_modified: '2026-01-26T07:07:48.863953'
source: obsidian
```
- ← [[Amyloid-Beta_4240_Ratio]] (biomarker)
```yaml
last_modified: '2026-01-26T07:07:09.882854'
source: obsidian
```
- ← [[BDNF]] (biomarker)
```yaml
last_modified: '2026-01-26T07:07:10.191066'
source: obsidian
```
- ← [[Blood_NfL]] (biomarker)
```yaml
last_modified: '2026-01-26T07:07:10.597897'
source: obsidian
```
- ← [[Digital_Biomarkers_for_Neurodegeneration]] (biomarker)
```yaml
last_modified: '2026-01-26T07:07:11.464163'
source: obsidian
```
- ← [[Neurofilament_Light_Chain]] (biomarker)
```yaml
last_modified: '2026-01-26T07:07:15.198842'
source: obsidian
```
- ← [[Neuron-Derived_Exosome_Biomarkers]] (biomarker)
```yaml
last_modified: '2026-01-26T07:07:15.353378'
source: obsidian
```
- ← [[Alpha-Synuclein_Aggregation]] (pathway)
```yaml
last_modified: '2026-01-26T07:08:10.957081'
source: obsidian
```
- ← [[Autophagy-Lysosomal_Pathway]] (pathway)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- ← [[Neuroinflammation]] (pathway)
```yaml
last_modified: '2026-01-26T07:08:12.428247'
source: obsidian
```
- → [[Autophagy-Lysosomal_Pathway]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Parkinsons_Disease]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Locus_Coeruleus]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Neurofilament_Light_Chain]] (biomarker)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Nigrostriatal_Dopamine_Pathway]] (entity)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Substantia_Nigra]] (entity)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Locus_Coeruleus]] (entity)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Basal_Ganglia]] (entity)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Mitophagy]] (pathway)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Coenzyme_Q10]] (supplement)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Striatum]] (entity)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Creatine]] (drug)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[DAT-SPECT]] (examination)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Levodopa]] (entity)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Pramipexole]] (entity)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Carbidopa]] (entity)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Rasagiline]] (entity)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Alpha-Synuclein_CSF]] (entity)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Alpha-Synuclein_Aggregation]] (pathway)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Deep_Brain_Stimulation]] (entity)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Omega-3_DHA]] (supplement)
```yaml
last_modified: '2026-01-26T07:07:35.297115'
source: obsidian
```
- → [[Neurofilament_Light_Chain]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Neuroinflammation]] (pathway)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Substantia_Nigra]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Alpha-Synuclein_CSF]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Retinal_Imaging_for_Neurodegeneration]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Digital_Biomarkers_for_Neurodegeneration]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Deep_Brain_Stimulation]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Sleep_Optimization]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Basal_Ganglia]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Nigrostriatal_Dopamine_Pathway]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Blood_NfL]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Omega-3_DHA]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Alpha-Synuclein_SAA]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Coenzyme_Q10]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Alpha-Synuclein_Aggregation]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Neuron-Derived_Exosome_Biomarkers]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Amyloid-Beta_4240_Ratio]] (entity)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[BDNF]] (biomarker)
```yaml
last_modified: '2026-01-26T06:47:49.397368'
source: obsidian
```
- → [[Parkinsons_Disease]] (condition)
```yaml
last_modified: '2026-01-26T06:03:53.109152'
source: obsidian
```
<!-- NEO4J_CONTENT_END -->
## Relationships

### Affected Brain Regions
- → [[Substantia Nigra]] (organ) - *Primary site of dopaminergic neuron loss*
- → [[Striatum]] (organ) - *Dopamine depletion target*
- → [[Locus Coeruleus]] (organ) - *Noradrenergic degeneration*
- → [[Basal Ganglia]] (organ) - *Motor circuit dysfunction*

### Associated Pathways
- → [[Nigrostriatal Dopamine Pathway]] (pathway) - *Primary affected pathway*
- → [[Mitophagy]] (pathway) - *Impaired mitochondrial quality control*
- → [[Alpha-Synuclein Aggregation]] (pathway) - *Core pathological process*

### Biomarkers
- ← [[Neurofilament Light Chain]] (biomarker) - *Marker of neurodegeneration*
- ← [[Alpha-Synuclein CSF]] (biomarker) - *Diagnostic potential*
- ← [[DAT-SPECT]] (examination) - *Dopamine transporter imaging*

### Treatments
- ← [[Levodopa]] (drug) - *Gold standard dopamine replacement*
- ← [[Carbidopa]] (drug) - *Peripheral decarboxylase inhibitor*
- ← [[Pramipexole]] (drug) - *Dopamine agonist*
- ← [[Rasagiline]] (drug) - *MAO-B inhibitor*
- ← [[Deep Brain Stimulation]] (intervention) - *Surgical treatment*

### Neuroprotective Supplements
- ← [[Coenzyme Q10]] (supplement) - *Mitochondrial support*
- ← [[Creatine]] (supplement) - *Energy metabolism*
- ← [[Omega-3 DHA]] (supplement) - *Anti-inflammatory*

## References
1. **Review**: Bloem, B.R., et al. (2021). "Parkinson's disease." *The Lancet*.
2. **Pathology**: Spillantini, M.G., et al. (1997). "Alpha-synuclein in Lewy bodies." *Nature*.